Fig. 2
From: Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase
Antinociceptive effects of morphine, SP600125 and their combination in the formalin test. Sub-additive antinociceptive effects of the combination of SP600125 (3 mg/kg i.p.) with morphine (6 mg/kg i.p.) is observed for (a) the composite pain score and area under the curve (AUC) of (b) Phase 1 and (c) Phase 2 pain behavior. Data are expressed as mean ± S.E.M. (n = 5–6 per group). *p < 0.0001 for SP600125 different doses vs. vehicle group (ANOVA, Bonferroni post hoc); + p < 0.021 vs. SP600125 group (ANOVA, Bonferroni post hoc); ^p < 0.039 morphine group vs. SP600125 (3 mg/kg) group (ANOVA, Bonferroni post hoc); x p < 0.0001 vs. vehicle group (ANOVA); #p < 0.044 vs. SP600125 (3 mg/kg) or morphine (6 mg/kg) (ANOVA, Bonferroni post hoc)